Young investors are not just hunting for the next unicorn—they are incubating the future of a technologically powerful nation.

Today, [Entrepreneur] officially unveiled its 2026 Young Venture Capital List. Zhu Pai, CEO of Efung Capital, has been named to the "Under 40 Investors" ranking, solidifying his position as a key driving force in the current wave of young venture capital.

Entrepreneur has long focused on the young venture capital community. Since 2013, it has held the "Under 40 Investors" selection for 14 consecutive years, aiming to identify capital visionaries who are active at the forefront of venture capital and riding the cutting edge. To date, the program has recognized 356 outstanding young investors.

This year's selection process evaluated candidates across three key dimensions: overall influence, investment performance, and exit performance, ultimately determining the final "Under 40 Investors" list.

According to the overall profile of the winners, young investors are increasingly becoming the backbone of the venture capital industry. The average age of the winners is 37.5, with the youngest being just 31; nearly 60% hold the position of partner or above. Their average investment experience spans 10.6 years, reflecting a balance of youth and deep expertise.

In terms of investment stage, "investing early, investing small, and investing in technology" remains the core strategy for young investors. They heavily favor early-stage and growth-stage tech companies, prioritizing original technological innovation and the efficiency of industrial transformation. They are fully committed to the potential of cutting-edge technologies to rapidly break through into real-world applications and drive transformation across entire industrial chains. Survey data shows that 75% of the winners focus on early-stage projects, while 20% are positioned in growth-stage projects—underscoring that the early-stage tech sector remains the primary battleground for investors.

Zhu Pai's selection is a powerful testament to Efung Capital's long-standing commitment to early-stage investing and its deep-rooted focus on the hard-tech sector. Looking ahead, Efung Capital will continue to uphold its core values of "professionalism, long-term commitment, and symbiosis" as it further deepens its presence in the biopharmaceutical field.